Closing the gap: PATROL’s approach to overcoming lung cancer diagnostic inequality

Share this article The high failure rate in ALS clinical trials is often attributed to the disease’s unclear aetiology and complex pathophysiology. Credit: ANDREI ASKIRKA

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

Phil Vick­ers start­ed last week as pres­i­dent and CEO of Solu Ther­a­peu­tics, a Long­wood Fund start­up de­vel­op­ing small mol­e­cule-an­ti­body chimeras. He takes the place of